Due to health issues, this site is no longer maintained and will be shut down shortly. |
Indaptus Therapeutics Inc is positioned to revolutionize the treatment of cancer and certain infectious diseases. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. Its pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
$1.90 +0.09 (4.97%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.